SEOVF
Sernova Biotherapeutics Inc
OTC Markets OTCPKUSDEQUITY
DELAYED
Neutral
-6/100
Last price
0.08
▲ 0.01 (8.04%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
0.08
Prev close
0.08
Day high
0.08
Day low
0.08
Volume
20.00K
Market cap
—
P/E (TTM)
—
52W range
0.06 – 0.14
Day trading desk
Gap from prior close
+5.88%
Prior close 0.08
VWAP
—
—
Relative volume
—
—
Session range
—
0.08 – 0.08
Position in range
—
—
ATR (14D)
0.01
7.99% of price
Prior day high
0.08
PDH
Prior day low
0.08
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Shares traded
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+5.88%
+3.9%
1M
-15.30%
-16.5%
3M
-5.89%
-10.4%
6M
-29.42%
-47.6%
YTD
-5.89%
-20.1%
1Y
-34.85%
-51.3%
3Y
-84.87%
-167.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Free account
3 more panels on SEOVF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $7.50M | $22.69M | $32.04M | $16.90M | -66.9% |
| Selling, general & admin | $7.50M | $8.94M | $8.43M | $7.83M | -16.1% |
| Total operating expense | $15.02M | $31.66M | $40.50M | $24.75M | -52.6% |
| Operating income | -$15.02M | -$31.66M | -$40.50M | -$24.75M | +52.6% |
| Net interest income | -$729.18K | -$198.47K | $1.47M | $459.28K | -267.4% |
| Pre-tax income | -$15.73M | -$32.19M | -$39.00M | -$24.42M | +51.1% |
| Tax provision | $9.43K | $7.00K | $0 | — | +34.7% |
| Net income | -$15.74M | -$32.19M | -$39.00M | -$24.42M | +51.1% |
| Net income to common | -$15.74M | -$32.19M | -$39.00M | -$24.42M | +51.1% |
| Basic EPS | -0.05 | -0.10 | -0.13 | -0.09 | +50.0% |
| Diluted EPS | -0.05 | -0.10 | -0.13 | -0.09 | +50.0% |
| EBIT | -$14.98M | -$31.60M | -$38.97M | -$24.30M | +52.6% |
| EBITDA | -$14.64M | -$31.06M | -$38.52M | -$23.86M | +52.9% |
| Basic shares | 328.29M | 306.95M | 303.33M | 273.59M | +6.9% |
| Diluted shares | 328.29M | 306.95M | 303.33M | 273.59M | +6.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $265.00K | $6.01M | $8.72M | $3.78M | — | -95.6% |
| Cash & short-term investments | $265.00K | $6.01M | $19.81M | $49.78M | — | -95.6% |
| Total current assets | $522.65K | $6.47M | $21.02M | $51.09M | — | -91.9% |
| Property, plant & equipment | $17.72K | $833.93K | $507.44K | $653.70K | — | -97.9% |
| Goodwill & intangibles | — | $0 | $316.72K | $516.75K | $716.78K | — |
| Total assets | $764.23K | $7.53M | $22.11M | $52.48M | — | -89.8% |
| Total current liabilities | $24.80M | $20.02M | $9.59M | $4.74M | — | +23.9% |
| Current debt | $3.73M | — | — | — | — | — |
| Long-term debt | $1.04M | — | — | — | — | — |
| Total debt | $4.77M | $569.94K | $136.12K | $275.98K | — | +737.6% |
| Total liabilities | $25.84M | $20.48M | $9.59M | $4.88M | — | +26.2% |
| Retained earnings | -$166.10M | -$150.36M | -$118.17M | -$79.17M | — | -10.5% |
| Shareholder equity | -$25.08M | -$12.96M | $12.51M | $47.61M | — | -93.5% |
| Working capital | -$24.27M | -$13.55M | $11.43M | $46.35M | — | -79.2% |
| Net tangible assets | -$25.08M | -$12.96M | $12.20M | $47.09M | — | -93.5% |
| Shares issued | 332.85M | 325.32M | 303.33M | 303.33M | — | +2.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$15.74M | -$32.19M | -$39.00M | -$24.42M | — | +51.1% |
| Depreciation & amortisation | $342.59K | $540.28K | $445.55K | $440.00K | — | -36.6% |
| Stock-based compensation | $2.30M | $1.75M | $3.90M | $7.45M | — | +31.9% |
| Change in working capital | $1.74M | $11.16M | $4.99M | $2.95M | — | -84.4% |
| Operating cash flow | -$10.91M | -$18.90M | -$30.34M | -$14.42M | — | +42.3% |
| Capital expenditure | — | — | -$99.26K | -$329.00K | -$17.23K | — |
| Investing cash flow | $24.96K | $11.12M | $34.78M | -$46.34M | — | -99.8% |
| Financing cash flow | $5.14M | $5.07M | $503.46K | $36.66M | — | +1.3% |
| Free cash flow | -$10.91M | -$18.90M | -$30.44M | -$14.75M | — | +42.3% |
| End cash position | $265.00K | $6.01M | $8.72M | $3.78M | — | -95.6% |
| Line item | 2026-07-31 | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $432.62K | $444.87K | $434.15K | $809.63K | $1.74M | — | -2.8% |
| Selling, general & admin | $1.69M | $1.85M | $1.68M | $1.58M | $1.75M | — | -9.0% |
| Total operating expense | $2.12M | $2.30M | $2.12M | $2.40M | $3.50M | — | -7.8% |
| Operating income | -$2.12M | -$2.30M | -$2.12M | -$2.40M | -$3.50M | — | +7.8% |
| Net interest income | -$260.18K | -$920.53K | -$477.12K | $260.60K | -$541.54K | — | +71.7% |
| Pre-tax income | -$2.57M | -$3.23M | -$2.41M | -$2.25M | -$4.05M | — | +20.3% |
| Tax provision | -$45.00K | $0 | -$72.00K | -$54.97K | $21.12K | — | — |
| Net income | -$2.53M | -$3.23M | -$2.33M | -$2.20M | -$4.07M | — | +21.6% |
| Net income to common | -$2.53M | -$3.23M | -$2.33M | -$2.20M | -$4.07M | — | +21.6% |
| Basic EPS | 0.01 | -0.01 | -0.01 | — | 0.01 | -0.01 | +200.0% |
| Diluted EPS | 0.01 | -0.01 | -0.01 | — | 0.01 | -0.01 | +200.0% |
| EBIT | -$2.31M | -$2.31M | -$1.93M | -$2.51M | -$3.51M | — | -0.3% |
| EBITDA | -$2.31M | -$2.30M | -$1.92M | -$2.45M | -$3.33M | — | -0.3% |
| Basic shares | 377.64M | 351.12M | 336.40M | — | 328.48M | 328.48M | +7.6% |
| Diluted shares | 377.64M | 351.12M | 336.40M | — | 328.48M | 328.48M | +7.6% |
| Line item | 2026-07-31 | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $63.33K | $1.05M | $576.22K | $265.00K | $83.62K | — | -94.0% |
| Cash & short-term investments | $63.33K | $1.05M | $576.22K | $265.00K | $83.62K | — | -94.0% |
| Accounts receivable | $10.89K | $116.84K | $125.59K | — | $266.05K | $432.98K | -90.7% |
| Total current assets | $369.58K | $1.53M | $775.67K | $522.65K | $499.75K | — | -75.8% |
| Property, plant & equipment | $4.43K | $8.86K | $13.29K | $17.72K | $187.11K | — | -50.0% |
| Total assets | $374.01K | $1.53M | $1.01M | $764.23K | $910.72K | — | -75.6% |
| Total current liabilities | $12.05M | $10.94M | $25.54M | $24.80M | $24.37M | — | +10.1% |
| Current debt | $2.50M | $2.22M | $3.86M | $3.73M | $3.65M | — | +12.6% |
| Long-term debt | $78.94K | $229.24K | $1.08M | $1.04M | $943.20K | — | -65.6% |
| Total debt | $2.58M | $2.45M | $4.94M | $4.77M | $4.69M | — | +5.3% |
| Total liabilities | $12.13M | $11.17M | $26.61M | $25.84M | $25.34M | — | +8.5% |
| Retained earnings | -$174.19M | -$171.67M | -$168.44M | -$166.10M | -$163.91M | — | -1.5% |
| Shareholder equity | -$11.75M | -$9.64M | -$25.60M | -$25.08M | -$24.43M | — | -21.9% |
| Working capital | -$11.68M | -$9.42M | -$24.76M | -$24.27M | -$23.87M | — | -24.0% |
| Net tangible assets | -$11.75M | -$9.64M | -$25.60M | -$25.08M | -$24.43M | — | -21.9% |
| Shares issued | 377.64M | 377.64M | 342.08M | 332.85M | 328.48M | — | 0.0% |
| Line item | 2026-07-31 | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$2.53M | -$3.23M | -$2.33M | -$2.20M | -$4.07M | +21.6% |
| Depreciation & amortisation | $4.43K | $4.43K | $4.43K | $62.22K | $185.05K | 0.0% |
| Stock-based compensation | $400.94K | $619.48K | $403.73K | $678.34K | $356.16K | -35.3% |
| Change in working capital | $533.07K | -$6.07K | $662.33K | $982.42K | $1.36M | +8,879.2% |
| Operating cash flow | -$989.83K | -$2.21M | -$1.05M | -$171.13K | -$2.07M | +55.2% |
| Investing cash flow | $0 | $0 | $0 | $20.17K | $4.78K | — |
| Financing cash flow | $0 | $2.68M | $1.36M | $332.34K | $153.44K | -100.0% |
| Free cash flow | -$989.83K | -$2.21M | -$1.05M | -$171.13K | -$2.07M | +55.2% |
| End cash position | $63.33K | $1.05M | $576.22K | $265.00K | $83.62K | -94.0% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.07
+15.29% from price
SMA 20
0.08
+10.38% from price
SMA 50
0.08
+6.82% from price
SMA 100
0.09
-6.25% from price
SMA 200
0.10
-17.06% from price
EMA 12
0.08
+9.72% from price
EMA 26
0.08
+9.01% from price
EMA 50
0.08
+4.70% from price
RSI (14)
56.4
Neutral
MACD (12,26,9)
-0.00
Hist 0.00
ATR (14)
0.01
7.99% of price
Realised vol 30D
159.4%
Annualised
Bollinger upper
0.10
20, 2σ
Bollinger lower
0.06
20, 2σ
50 / 200 cross
Death
0.08 vs 0.10
Trend bias
Below 200
-17.06%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-0.03
Less volatile than market
Correlation to SPY
-0.00
Largely independent
Realised vol 30D
159.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-57.1%
Peak to trough
Max drawdown 5Y
-96.4%
Peak to trough
ATR 14
0.01
7.99% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial
GlobeNewswire · 3d ago
Sernova Biotherapeutics to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference
GlobeNewswire · 13d ago
Steven Sangha Announces Voting and Support Agreement for Sernova Biotherapeutics Inc.'s Proposed Business Combination with Seraxis Holdings, Inc.
TMX Newsfile · 26d ago
Sernova Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investor Conference
GlobeNewswire · 28d ago
Sernova and Seraxis Enter Definitive Merger Agreement to Create a Differentiated Type 1 Diabetes Islet Cell-Replacement Biotech Company, BetaNova Biotherapeutics
GlobeNewswire · 30d ago
Cell Encapsulation Global Market Report 2026-2035 | Features Strategic Profiles of Beta-Cell, Betalin Therapeutics, Beta-O2 Technologies, Diatranz Otsuka, Neurotech, Semma Therapeutics, Sernova, ViaCyte
GlobeNewswire · 43d ago
A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up
CNW Group · 79d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.